Abstract【Objective】To investigate the changes of serum insulin-like growth factor binding protein 2 (IGFBP2) and microRNA-29c (miR-29c) levels in patients with glioma and their clinical significance. 【Methods】Eighty patients with glioma diagnosed in our hospital from January 2016 to December 2017 (case group), 80 healthy subjects with age, gender and case group were selected as the control group, and the serum of the two groups were tested. IGFBP2 and miR-29c levels were analyzed by stratification according to tumor diameter, pathological type, WHO classification, and tumor location. 【Results】The level of serum IGFBP2 in the observation group was significantly higher than that in the control group, and the level of serum microRNA-29c was significantly lower than that in the control group, with statistical significance (P<0.05). The serum levels of IGFBP2 and microRNA-29c in patients with WHO grade Ⅲ were significantly higher than those in patients with WHO grade Ⅰ and Ⅱ, while the serum levels of microRNA-29c were significantly lower than those in patients with WHO grade Ⅰ and Ⅱ (P<0.05); there was no significant difference in serum levels of IGFBP2 and microRNA-29c between patients with different pathological types, lesion diameters and tumor sites (P>0.05). 【Conclusion】The level of serum IGFBP2 increases and the expression of microRNA-29c decreases in glioma patients, which is correlated with the grade of glioma.
2019, Vol. 36 
